They joined us!
Date of creation: 20 octobre 2025
Number of employees: 5
Locations / Sites of operation: Tours
Field of activity (biotech/medtech/digital healthtech): Biotech
Who are they?
SAPPIENS is a clinical-stage biotech pioneering first-in-class disease-modifying therapies for Parkinson’s disease and ALS, two devastating neurodegenerative diseases with major unmet needs. Its lead candidate, CXS003, is a patented therapy designed to simultaneously target three key drivers of neurodegeneration: oxidative stress, neuro-inflammation, and mitochondrial dysfunction. SAPPIENS combines experienced leadership, deep scientific expertise, strong Scientific Advisory Boards, and leading KOL networks.
Why did they join Lyonbiopole?
We joined Lyonbiopole to connect with a strong ecosystem of life sciences companies, experts, and strategic partners. We value its ability to facilitate high-quality connections, strengthen our visibility, and support our development. We particularly expect to benefit from its network, expertise, and international reach as we advance CXS003 toward clinical proof of concept.
Gabrielle GACHE – Chief Executive Officer
